[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636137":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":21,"responsibleParty":32,"collaborators":21,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":21,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":21,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":60,"whyStopped":21,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":21},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adebrelimab plus S-1","EXPERIMENTAL","Participants will receive adebrelimab in combination with S-1 as adjuvant therapy after curative resection. Adebrelimab will be administered intravenously at 1200 mg every 3 weeks for 4 cycles. S-1 will be administered orally at 40 mg\u002Fm² twice daily on Days 1-28 of a 6-week cycle, followed by a 2-week rest, for 4 cycles.",[13,14],"Drug: Adebrelimab","Drug: S-1",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Adebrelimab","Adebrelimab will be administered intravenously at a dose of 1200 mg on Day 1 of each 3-week cycle for a total of 4 cycles as adjuvant therapy after curative resection.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"S-1","S-1 will be administered orally at a dose of 40 mg\u002Fm² twice daily on Days 1-28 of each 6-week cycle, followed by a 2-week rest period, for a total of 4 cycles.",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Xingjun Guo","CONTACT","027-83665315","xjguo@tjh.tjmu.edu.cn",{"type":33,"investigatorFullName":28,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Doctor","100636137","phase-2-adebrelimab-plus-s-1-for-resected-cholangiocarcinoma-100636137",false,"NCT07561775","Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","A Single-Arm, Exploratory Clinical Study of Adebrelimab Combined With S-1 in Patients With Resected Cholangiocarcinoma","Inclusion Criteria:\n\n* Histologically or pathologically confirmed malignant cholangiocarcinoma.\n* Patients who have undergone curative surgical resection.\n* Age between 18 and 75 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected survival time \\>3 months.\n* Adequate organ and bone marrow function, including:Absolute neutrophil count ≥1.5 × 10\\^9\u002FL,Platelet count ≥75 × 10\\^9\u002FL,Hemoglobin ≥90 g\u002FL,Total bilirubin ≤1.5 × upper limit of normal (ULN),AST and ALT ≤2.5 × ULN,Albumin ≥3 g\u002FdL,Serum creatinine ≤1.5 × ULN.\n* Ability to understand and willingness to sign written informed consent.\n* For patients of childbearing potential, willingness to use effective contraception during the study and for at least 1 month after the last dose; negative pregnancy test within 72 hours prior to enrollment.\n\nExclusion Criteria:\n\n* Prior treatment with immune checkpoint inhibitors or other agents targeting T-cell co-stimulatory or co-inhibitory pathways (e.g., CTLA-4, CD137).\n* Use of any investigational drug within 4 weeks prior to enrollment.\n* Active autoimmune disease or history of autoimmune disease (e.g., interstitial lung disease, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, or hypothyroidism requiring hormone replacement).\n* Known immunodeficiency, including HIV infection, active hepatitis B (HBV DNA \\>500 IU\u002FmL), active hepatitis C (HCV RNA above detection limit), or co-infection of HBV and HCV.\n* Severe infection within 4 weeks prior to first dose or unexplained fever \\>38.5°C during screening.\n* History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Uncontrolled psychiatric disorders.\n* Severe or uncontrolled comorbidities that may interfere with study participation (e.g., unstable angina, myocardial infarction within 6 months, symptomatic arrhythmia, congestive heart failure, uncontrolled diabetes, or uncontrolled infection).\n* History of other malignancies within the past 5 years, except for non-melanoma skin cancer or carcinoma in situ.\n* Known hypersensitivity to study drugs or monoclonal antibodies.\n* Inability or unwillingness to provide informed consent.","ALL","18 Years","75 Years",{"count":46,"type":47},40,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2","The goal of this clinical trial is to learn whether adebrelimab combined with S-1 works as an adjuvant treatment for patients with cholangiocarcinoma after curative surgery. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n* Does adebrelimab combined with S-1 reduce the risk of cancer recurrence after surgery?\n* What side effects do participants experience when receiving this treatment? All participants in this study will receive adebrelimab combined with S-1. There is no comparison group in this study.\n\nParticipants will:\n\n* Receive adebrelimab by intravenous infusion once every 3 weeks for 4 cycles\n* Take S-1 by mouth twice daily for 4 weeks, followed by a 2-week rest, for 4 cycles\n* Visit the hospital regularly for checkups, laboratory tests, and imaging examinations (CT or MRI)\n* Be followed up for safety and survival after completing treatment",[53,54],"Cholangiocarcinoma","Biliary Tract Cancer",[18,23,56,57,58,59],"Adjuvant Therapy","Postoperative Treatment","PD-L1 Inhibitor","Immunotherapy","NOT_YET_RECRUITING","2026-04-25",{"date":63,"type":64},"2026-05-01","ACTUAL",{"date":66,"type":47},"2026-04-21",{"date":68,"type":47},"2032-01-01",{"name":28,"class":6}]